Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Onyx Rejected by U.S. in Request for Faster Cancer-Drug Review

Onyx Pharmaceuticals Inc.’s experimental cancer drug carfilzomib will get a standard review from U.S. regulators, instead of an accelerated process sought by the company.

The Food and Drug Administration said the South San Francisco, California-based company hadn’t conducted the clinical trials necessary for the quicker review of carfilzomib, Onyx said today in a statement.

The FDA scheduled a target date of July 27, four months later than under an accelerated approval, to decide whether to approve carfilzomib for patents with multiple myeloma, a cancer of plasma cells, Onyx said in its statement. The company, which developed Nexavar for kidney cancer, submitted its application in September.

“Our goal remains to make this promising new therapy available to patients with relapsed and refractory multiple myeloma as quickly as possible,” Ted Love, Onyx’s executive vice president of research and development, said in the statement.

Carfilzomib may generate $227.6 million in sales by the end of 2014, according to the average estimate of four analysts surveyed by Bloomberg.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.